A Nasal Spray for Rapid Heartbeat Disorder Could Be Best Option for Self-Treatment, Study Shows

Note: This article is for informational purposes only and is not a substitute for medical advice, diagnosis, or emergency care. A racing heart can have more than one cause, and not every episode is safe to manage at home.

There are few things more dramatic than your heart suddenly acting like it just chugged six espressos and signed up for a sprint. One minute you are answering emails, folding laundry, or pretending to enjoy a family group chat. The next, your chest is pounding, your pulse is racing, and your brain is trying to decide whether this is stress, a panic attack, or a plot twist. For many adults with paroxysmal supraventricular tachycardia, or PSVT, that abrupt “here we go again” feeling is painfully familiar.

Now, a self-administered nasal spray is changing the conversation. Newer clinical findings, combined with U.S. regulatory approval, suggest that etripamil nasal spray may offer something patients with recurrent rapid heartbeat episodes have wanted for years: a fast, practical option they can use themselves outside the hospital. That matters because PSVT is not always dangerous, but it is often disruptive, frightening, and inconvenient enough to send people straight to urgent care or the emergency room.

And let’s be honest, “Please proceed to the emergency department for your inconveniently timed arrhythmia” is not exactly a user-friendly wellness plan.

What Is PSVT, and Why Does It Feel So Alarming?

PSVT is a type of arrhythmia, meaning an abnormal heart rhythm, that starts above the ventricles in the upper part of the heart. It usually begins and ends suddenly. That “paroxysmal” part is medicine’s fancy way of saying, “It shows up uninvited, causes chaos, and sometimes leaves just as abruptly.”

During an episode, the heart can beat very fast and very regularly. People often describe pounding palpitations, chest discomfort, shortness of breath, lightheadedness, dizziness, weakness, or a sensation that something is very much not normal. In some cases, PSVT is misread as anxiety or panic because the symptoms overlap, but the mechanism is different: the heart’s electrical system gets caught in a looping signal that keeps triggering rapid beats.

That is what makes PSVT both medically important and emotionally exhausting. It may not always be a catastrophe, but it rarely feels casual. In the United States, the condition is common enough to matter at scale, with estimates suggesting roughly 1 in 300 people may experience PSVT. That is a lot of people learning far more about cardiac electrophysiology than they ever planned.

How PSVT Is Usually Managed

Traditional PSVT care often starts with vagal maneuvers, which are physical techniques meant to stimulate the vagus nerve and slow the heart. These can include bearing down, coughing, or using a cold stimulus on the face. Sometimes they work. Sometimes they work about as reliably as a Wi-Fi signal in the back room.

If the rhythm does not stop, medical treatment may be needed. In supervised settings, clinicians may use intravenous drugs such as adenosine to break the episode. For recurrent or especially bothersome cases, catheter ablation can be a highly effective longer-term solution by targeting the electrical pathway causing the arrhythmia. For many patients, ablation remains the closest thing to a definitive fix.

Still, not everyone is ready for a procedure, eligible for one, or able to get one immediately. And oral “pill-in-the-pocket” strategies have limits. They can be slower, less predictable for acute episodes, and not always ideal from a safety or convenience standpoint. That gap between “try a maneuver” and “go to the ER” is exactly where interest in a fast-acting nasal spray took off.

Why a Nasal Spray Is Getting So Much Attention

Etripamil is a rapid-acting calcium channel blocker designed for intranasal use. Instead of waiting for a pill to be digested and absorbed, the medication is delivered through the nose for quick uptake. In plain English, it is trying to beat the clock.

For people with PSVT, speed matters. A treatment that works quickly at home can mean less time feeling awful, less time wondering whether things will spiral, and potentially fewer trips to acute care. That is why the idea is so compelling. It is not just about drug delivery. It is about restoring a sense of control during a moment that often feels wildly out of control.

The concept also lines up with how patients actually experience PSVT. Episodes are often intermittent. They happen at home, at work, in the car, at the grocery store, or at 2:13 a.m. when the rest of the household is asleep and the only thing louder than your heartbeat is your internal monologue. A treatment that can travel with the patient makes practical sense.

What the Study Results Show

The most important data come from the phase 3 RAPID trial and follow-up analyses of recurrent episode treatment. In RAPID, adults with symptomatic PSVT self-administered etripamil nasal spray during episodes outside the hospital. If symptoms persisted after 10 minutes, they could use a second dose. The results were hard to ignore.

Within 30 minutes, 64% of patients using etripamil returned to normal heart rhythm, compared with 31% of those using placebo. The median time to conversion was about 17 minutes for the nasal spray group versus roughly 54 minutes for placebo. That is not a tiny difference. That is the difference between “this might pass eventually” and “this is actually doing something.”

Longer-term follow-up in recurrent episodes reinforced the promise. Across positively adjudicated PSVT episodes in an extension study, the probability of conversion within 30 minutes was about 60.2%, with a median time to conversion of 15.5 minutes. Within 60 minutes, about 75.1% of episodes had converted. Researchers also reported that the drug was generally well tolerated when used for repeated episodes without direct medical supervision.

In 2025, a secondary analysis added another important angle: healthcare use. Patients who self-administered etripamil were less likely to end up in the emergency department for ongoing PSVT symptoms than patients receiving placebo. That may sound like a dry utilization statistic, but for patients, families, and crowded emergency rooms, it is a very real quality-of-life win.

FDA Approval Changes the Story

This stopped being just an interesting research topic and became a real-world treatment story when the U.S. Food and Drug Administration approved Cardamyst, the brand name for etripamil nasal spray, in December 2025 for acute symptomatic episodes of PSVT in adults.

That matters for two reasons. First, approval means the therapy cleared the FDA’s review of the available evidence on safety and effectiveness for its indicated use. Second, it shifts the discussion from “experimental option” to “available outpatient tool,” at least for the right patient population.

The approved dosing is straightforward: one device delivers a 70 mg dose using one spray in each nostril. If symptoms persist after 10 minutes, a second 70 mg dose may be used. The maximum is 140 mg in 24 hours. Simple instructions are not a small detail here. During a tachycardia episode, nobody wants a medication routine that requires advanced algebra and a calm philosophical mindset.

Why It May Be the Best Self-Treatment Option for Some Adults

The keyword is some. The nasal spray is not automatically the best option for every patient with every fast heartbeat. But for appropriately selected adults with documented PSVT, the case for it is strong.

1. It works fast.

That may be its biggest advantage. Acute arrhythmia treatment is one area where “eventually” is not a satisfying feature. Rapid conversion can reduce symptoms, reduce fear, and reduce the odds that a patient decides they need emergency care.

2. It is designed for use outside a healthcare setting.

This is the headline feature. Etripamil was built around the real-life problem of sudden episodes happening away from clinicians, monitors, and IV carts. It is self-administered, portable, and tailored to the on-demand nature of PSVT.

3. It may reduce ER dependence.

That does not mean nobody using it will ever need medical care. It means some patients may avoid unnecessary emergency visits when a familiar, confirmed PSVT episode starts and responds quickly to treatment.

4. It gives patients a sense of agency.

Anyone who has lived with recurrent arrhythmia knows part of the burden is psychological. Episodes can create dread, scheduling anxiety, travel anxiety, exercise anxiety, and “please not during this meeting” anxiety. A reliable rescue treatment can ease that burden in a meaningful way.

Important Safety Limits and Caveats

This is not a spray-and-forget miracle. Cardamyst has important warnings, common side effects, and specific contraindications. The most common side effects reported have involved the nose and throat area, including nasal discomfort, congestion, runny nose, throat irritation, and nosebleeds. The medication can also cause dizziness or fainting, so patients are advised to use it while sitting down and in a place where a fall is less likely.

It is also not appropriate for everyone. The FDA labeling lists several contraindications, including certain conduction disorders, some patients with heart failure, and conditions such as Wolff-Parkinson-White syndrome with pre-excitation. That is why this treatment belongs in a doctor-guided plan, not a random bathroom cabinet next to expired cold medicine and a mystery vitamin from 2022.

Most importantly, not every racing heartbeat is PSVT. A person with new symptoms, severe chest pain, fainting, significant shortness of breath, or uncertainty about the diagnosis needs medical evaluation. Self-treatment works best when the problem has already been clearly identified and a clinician has explained when and how to use the medication.

Will It Replace Ablation or Emergency Care?

Probably not across the board, and it does not need to. Catheter ablation remains an excellent option for many patients with recurrent symptomatic PSVT, especially when the goal is long-term prevention rather than rescue treatment. Emergency care will still be necessary for severe, complicated, or unclear cases.

But that is not a weakness of the nasal spray. It is a sign that treatment should be individualized. In many patients, the best care path may involve more than one option: vagal maneuvers as the first move, a prescribed nasal spray as an at-home rescue therapy, and ablation as a future definitive treatment if episodes remain frequent or disruptive.

That layered approach is probably where the biggest clinical value lies. The nasal spray does not erase the need for specialists. It gives those specialists another tool, and it gives patients another chance to handle an episode before it turns into a full-scale detour through emergency medicine.

Experience: What Life Around PSVT Really Feels Like

To understand why a self-treatment nasal spray has generated so much excitement, it helps to understand the experience of living with PSVT. The hardest part is not always the duration of an episode. Often, it is the unpredictability. Many people describe feeling fine for days, weeks, or even months, then suddenly being jolted by a rapid, pounding heartbeat that seems to come out of nowhere. The interruption itself can be unsettling. You are not just dealing with symptoms. You are dealing with the loss of trust in your own body’s timing.

Patients often talk about the strange combination of physical discomfort and mental negotiation. Is this an episode that will stop in five minutes? Should I lie down? Should I try a maneuver? Is it safe to drive? Do I call someone? Do I ride it out? That uncertainty can make even a short event feel much longer. Some people become hyperaware of every skipped beat or flutter afterward, which can create a cycle of vigilance and stress.

Then there is the practical burden. Recurrent PSVT can hijack workdays, social plans, exercise routines, and sleep. A person who has already had one late-night ER trip for a fast rhythm may spend the next several months quietly planning around the possibility of another. That means avoiding travel, avoiding being alone, or carrying an invisible level of “just in case” concern everywhere they go. Even when episodes are not frequent, the anticipation can be draining.

That is why the idea of self-treatment resonates so deeply. It is not only about shortening an episode. It is about restoring predictability. Patients often value treatments that let them respond quickly and privately, without automatically escalating every event into a medical crisis. For the right person, being able to reach for a prescribed rescue spray instead of racing to urgent care may feel less like convenience and more like relief.

Clinicians see another side of the experience. They know many PSVT patients are otherwise healthy, active adults who do not look “cardiac” in the stereotypical sense. Yet the symptoms can still be intense enough to send them to the hospital. That mismatch sometimes leads to delays in diagnosis or the mistaken assumption that the problem is primarily anxiety-related. When a condition has abrupt onset, dramatic symptoms, and spontaneous resolution, it can be easy for outside observers to underestimate how disruptive it really is.

Family members experience it too. They are often the ones watching a loved one go pale, become dizzy, or suddenly stop mid-conversation to sit down and breathe through a racing pulse. They may feel helpless, especially if episodes happen repeatedly but unpredictably. A well-designed treatment plan can reduce fear for the whole household, not just the patient.

In that context, the nasal spray represents more than a medication. It represents a new kind of episode plan. Not the old plan of “try not to panic while deciding whether this is bad enough.” A better plan. A clearer plan. A plan with instructions, a time frame, and a stronger sense that the patient has options.

Final Thoughts

The idea that a nasal spray could become a leading self-treatment option for a rapid heartbeat disorder might have sounded far-fetched a few years ago. Now it sounds practical. Etripamil nasal spray has moved beyond curiosity status thanks to strong trial results, real-world follow-up data, and FDA approval for adults with symptomatic PSVT.

That does not mean it is the best choice for every patient. It does mean it may be one of the most promising self-treatment tools yet for adults with a confirmed diagnosis, especially those who want a fast, portable, doctor-guided rescue option for episodes that strike outside the clinic.

In medicine, the best innovations are not always the flashiest. Sometimes they are the ones that meet patients exactly where their problem happens: at home, on the go, and usually at the most inconvenient moment possible. For many people with PSVT, that may be exactly what this nasal spray does.